Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
  • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
  • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
  • A61K31/355—Tocopherols, e.g. vitamin E
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
  • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/4841—Filling excipients; Inactive ingredients
  • A61K9/4858—Organic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/4891—Coated capsules; Multilayered drug free capsule shells

Definitions

• the present invention provides for a stable oral pharmaceutical composition containing an acid labile benzimidazole compound as active ingredient.
• the active ingredient in said formulation being stabilized which a vitamin E derivative.
• the invention relates also to a cost effective manufacturing process for the preparation of said stable pharmaceutical dosage form. More particularly the manufacturing process comprises the filling in to gelatin and/or hydroxypropylmethylcellulose capsules of the mixed melted ingredients with the active drug. The capsules being thereafter optionally enteric coated.
• Acid labile benzimidazole compounds comprise 2[2(pyridyl) methylsulfinyl] - benzimidazole or a derivative thereof (hereinafter sometimes referred to collectively as "benzimidazole compounds' " ) particularly the derivatives 2-[[3 methyl - 4 - (2,2,2 trifluoro methoxy) - 2 - pyridyl] methyl sulfinyl] benziminazole and 5 - methoxy - 2 - [(4 - methoxy - 3, 5 -dimethyl - 2 - pyridyl) methylsulfinyl] benzimidazole which are useful as anti-ulcer agent.
• enteric coating bases such as cellulose acetate phthalate, hydroxypropylmethylcellulose acetate succinate and Eudragit (methacrylic acid-acrylic acid copolymer) have poor compatibility with said compounds and cause content decrease and color change.
• enteric coating bases such as cellulose acetate phthalate, hydroxypropylmethylcellulose acetate succinate and Eudragit (methacrylic acid-acrylic acid copolymer) have poor compatibility with said compounds and cause content decrease and color change.
• enteric coating bases such as cellulose acetate phthalate, hydroxypropylmethylcellulose acetate succinate and Eudragit (methacrylic acid-acrylic acid copolymer) have poor compatibility with said compounds and cause content decrease and color change.
• Eudragit methacrylic acid-acrylic acid copolymer
• US Patent 4786505 describes a pharmaceutical preparation containing omeprazole together with an alkaline reacting compound or an alkaline salt of omeprazole optionally together with an alkaline compound as the core material, one or more sub-coating layer comprising inert reacting compounds which are soluble or rapidly disintegrating in water, or polymeric, water soluble filmforming compounds, optionally containing pH-buffering alkaline compounds and enteric coating.
• US Patent 5093132 describes a stabilized pharmaceutical composition
• a stabilized pharmaceutical composition comprising: an effective amount of a 2-benzimidazole derivative selected from the group consisting of 2- benzimidazole and 5-methoxy-2-benzimidazole, or a pharmaceutically acceptable salt thereof; a basic inorganic salt stabilizing agent which is present in an amount effective to stabilize the composition, the benzimidazole derivative being in contact with the basic inorganic salt evenly; and an enteric coating for the composition.
• US Patent 5385739 describes a stable formulation of omeprazole microgranules containing a neutral core consisting of sugar and starch, characterized in that it contains an active layer consisting of a dilution of omeprazole in mannitol in substantially equal amounts.
• US Patent 5399700 describes a method for stabilizing an acid-unstable compound by forming an inclusion complex of omeprazole with cyclodextrin comprising: dissolving cyclodextrin in an aqueous alkaline solution at 40° to 70 °C, and reacting said omeprazole with a cyclodextrin for 1 to 30 minutes in said alkaline solution, the ratio of said acid-ustable compound to said cyclodextrin in said reaction being from about 1 :1 to about 1 : 10, on a number of moles basis.
• US Patent 5639478 describes a method of stabilizing an enteric coated anti-ulcer composition, which comprises: homogeneously admixing an effective amount of a 2-[(2- pyridyl) methylsulphinyl] -benzimidazole compound or a pharmaceutically acceptable salt thereof having a gastric acid secretion inhibitory property with a basic inorganic salt stabilizing agent; granulating the mixture; and enteric coating the granules.
• US Patent 5626875 describes a stable oral pharmaceutical preparation containing an acid benzimidazole compound, which comprises: (a) A nucleus formed by an inert core, the acid labile benzimidazole compound, a non-alkaline inert water soluble polymer and non-alkaline reacting pharmaceutical acceptable excipients; (b) an inert non-alkaline coating disposed on said nucleus, formed by a non-alkaline water soluble polymer and non-alkaline pharmaceutical excipients. and (c) an outer layer disposed on the previous coating comprising an enteric coating.
• the present inventors made investigations for a new cost efficient manufacturing process for the preparation of stable pharmaceutical formulations containing acid labile benzimidazole compounds and. as a result, have completed the present invention.
• the object of the present invention is to obtain a pharmaceutical composition comprising an acid labile benzimidazole compound that possesses excellent storage stability.
• Another object of the present invention is to obtain a stable benzimidazole compound pharmaceutical composition using a simplified and/or cost effective manufacturing process involving encapsulation into hard and/or soft gelatin and/or HPMC capsules of the molten excipients with the active benzimidazole compound.
• Another object of the invention is to protect the formulation from the stomach acid juices by enteric coating the capsules.
• the object of the present invention is to provide an oral enteric coated form of acid labile benzimidazole compounds, ensuring good stability and good bioavauability of said compounds and a simple and cost effective manufacturing process thereof.
• the new dosage form is characterized in the following way: the acid labile benzimidazole compound is formulated in a semi-solid form containing a mixture of a lipophilic solubilising and/or supending inactive ingredients with a vitamin E derivative stabilizer. This liquids mix is then filled in to capsules. Which are thereafter enteric coated to protect the .benzimidazole compound from the gastric acids.
• the present invention relates to a stable, gastro-enteric semi-solid formulation of acid labile benzimidazole compound providing a good bioavauability of the drug and a cost effective manufacturing process thereof.
• the composition described comprises at least one lipophilic inactive ingredient and a derivate of «-tocopherol (Vitamin E) as stabilizing agent, in order to prevent the degradation of the acid labile benzimidazole compound.
• the Vitamin E derivative may also acts as a co-solubilizer agent.
• the lipophilic excipients chosen must allow the release of the acid labile benzimidazole compound very rapidly in the proximal parts of the small intestine, in order to obtain good bioavauability of the drug.
• the acid labile benzimidazole compound is added and mixed to a molten mixture of excipients.
• This mixture comprises the lipophilic constituents and the stabilizing agent.
• the temperature of the mixture is maintained sufficiently high during the whole process to maintain the mixture in a liquid state. Capsules filled with the liquid mixture are thereafter enteric coated.
• the benzimidazole compound for the use in this invention have potent gastric acid antisecretory activity, gastric mucosa-protecting activity and antiulcer activity and, yet, a low toxic potential and, therefore, can find application in the treatment of peptic ulcer in malian animals (e.g. mouse, rat, rabbit, dog, cat and man).
• malian animals e.g. mouse, rat, rabbit, dog, cat and man.
• the benzimidazole compounds having antiulcer activity for use in this invention includes, among specific examples, 2-[2-[3-methyl-4-2(2,2,2- trifluoroethoxy)pyridlyl]methylsulf ⁇ nyl]benzimidazole (lansoprazole), 2-[2-[3-methyl-4-(2,2,3,3- tetrafluoropropoxy)pyridyl]methylthio] benzimidazole, 2-[(2- pyridyl)methyldulifyl]benzimidazole (thimoprazole), 2-[2-(3,5-dimethyl-4- methoxypryridyI)methylsulfinyl]-5-methoxy-lH-benzimidazole (omeprazole), 2-[2-[4-(3- mehoxypropoxy)-3-methylpyridyl]methylsulfinyl — 1 H-benzimidazole, 2-[2-(3,4- dimethoxypyridyl)methyl
• benzimidazole compounds for use in this invention may be present as racemates and/or as individual stereoisomers.
• Lipophilic pharmaceutical acceptable excipients usefull for the present invention include vegetable and/or animal oils, and/or synthetic triglycerides.
• the preferred oils are mono, di or triglycerides saturated or unsaturated fatty acids (e.g. palmitic acid, caprylic acid, capric acid, lauric acid, myristic acid, oleic acid, linolenic acid, laurolenic acid. etc.).
• Still more desirable are the triglycerides of C8 - C18 saturated fatty acids such as coconut oil (akomed®) hydrogenated soja bean oil (akosol®), synthetic triglyceride of saturated fatty acids (Gelucire 33/01).
• the more desirable lipohilic pharmaceutical acceptable excipient usefull for the present invention can be. at least partially, characterized by a low hydroxyl and iodine values.
• the stabilizing agent for use in this invention includes a vitamin E or Vitamin E derivative such as d or dl alpha tocopherol, d or dl alpha tocopherol acetate, d or dl alpha tocopherol acid succinate.
• Vitamin E Polyethylene Glycol succinate vitamine E TPGS®kodak.
• the enteric coating is applied onto the capsule after cooling.
• the enteric polymer may be chosen among, but are not restricted to cellulose acetate phtalate, polyvinyl acetate phtalate, Hydroxypropylmethylcellulose phtalate. co-polymerized methacrylic acid or similar compounds widely used in the pharmaceutical industry to obtain enteric coatings.
• the enteric dispersion may be either an aqueous dispersion (EUDRAGIT L30D-55 ® , Rohm- Pharma. SURRETERIC ® , Colorcon) or hydro-ethanolic dispersion and/or solutions (HP 50 ® and HP 55*, Shin-Etsu).
• EUDRAGIT L30D-55 ® Rohm- Pharma. SURRETERIC ® , Colorcon
• hydro-ethanolic dispersion and/or solutions HP 50 ® and HP 55*, Shin-Etsu
• the enteric coating layer may contain a pharmaceutically acceptable plasticizer.
• a pharmaceutically acceptable plasticizer such as for instance triacetic citric acid esters, dibutyl succinate, phtalic acid esters, propylene glycol, diethyltartarate, acetylated monoglycerides.
• the preparation according to the invention consists in a stable semi-solid composition filled into capsules which are enteric coated.
• the capsules obtained are insoluble in acidic media but are rapidly dissolved in neutral and alkaline media.
• a process for the manufacturing of the oral dosage form represents a further aspect of the invention.
• the simplicity and the low cost of the proposed process may indeed be considered as advantage in comparison to existing manufacturing processes.
• the acid labile benzimidazole compound is incorporate to the molten mix, which contains the lipophilic inactive ingredients and the stabilizing agent. Once homogeneous, the liquid is filled into hard gelatin or HPMC capsules. The capsules are thereafter enteric-coated using a fluidzed bed coater and/or any other acceptable coating equipment.
• Acid labile benzimidazole compound (omeprazole) in mixture with Soja oil.
• lOg of omeprazole base is added to 190g Soja bean oil.
• 200mg of the mixture is introduced in hard gelatine capsules.
• omeprazole base 20g is added to a molten mixture of 150g of Soja oil and 75g of Vitamin E Polyethylene Glycol Succinate.
• the capsules were stored at room temperature and after 1 week no change in color was detected, demonstrating good stability of the acid labile benzimidazole compound.
• cample 4 20g of omeprazole base was added to a molten mixture of 150g of Soja oil and lOOg of Vitamin E Polyethylene Glycol Succinate. 270mg of the mixture was introduced into hard Hydroxypropylmethylcellulose capsules. The capsules were stored at room temperature and after 1 week no change of color was observed demonstrating good stability characteristics. cample 4:
• a beaker In a beaker, add the olive oil and heat at 37°C. Start agitation, add the Vitamin E derivative and thereafter the omeprazole and continue mixing for about half hour. Fill gelatine capsules size 3 with 107.5mg of the hot mixture. The stability of these formulations were measured by observation of the color of the capsule content. It is known that omeprazole color changes from white to dark brown while degradating.
• composition of formulation 4a Upon storage a room temperature, the composition of formulation 4a changed color after 2 days while the formulation 4b showed some color changes after 4 days, the composition of formulation 4c did not show any color change after 1 week.
• example 5 were prepared as in example 4.
• the formulation stability was evaluated by the color changes of the capsule content.
• the capsules were stored at room temperature and observed daily for color change.
• composition of example 5a had a light change in color after 4 days while composition of example 5b has a very light change in color after 6 days.
• the composition of example 5c did not show any change of color after 2 weeks of observations.
• Example 6 (capsules + coating):
• the capsules were prepared using preparation method from example 4. Each capsule contained 20mg of omeprazole. Thereafter they were coated using a STREA1 fluidized bed coater with 20 % of dry coating of the following coating suspension:
• Example 7 Upon coating capsules were dried in an oven at 35 °C for 8 hours. The capsules were further packaged in HDPE bottles containing 30 capsules and a 0.5g desiccant. These packaged capsules underwent a stability program at 25 °C and 60% relative humidity. The percent of omeprazole versus theoretical amount was determined and was found at 101% initially, 102% after 8 months and 102% after 14 months. These results demonstrate that the formulation of example 6 is stable.
• Example 7 Example 7:
• the hot liquid suspension is transferred to an encapsulating machine and filling hard gelatine capsules size #3 with 46mg (8mg of omeprazole) or 92mg (16mg of omeprazole) of blend is performed.
• the enteric coated capsules are thereafter dried for about 8 hours in an oven at 35 °C.
• the capsules are packaged in High Density Polyethylene bottles containing 30 capsules and 0.5g of desiccant.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Engineering & Computer Science (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=22604612

Family Applications (1)

Country Status (4)

Families Citing this family (1)

Family Cites Families (3)

• 2000
  • 2000-11-22 AU AU15453/01A patent/AU1545301A/en not_active Abandoned
  • 2000-11-22 WO PCT/IB2000/001842 patent/WO2001037834A1/en not_active Application Discontinuation
  • 2000-11-22 EP EP00977823A patent/EP1259238A1/de not_active Withdrawn
  • 2000-11-22 CA CA002392353A patent/CA2392353A1/en not_active Abandoned

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events